Overview of This Market Study:
The study involved four major activities to estimate the current size of the Human Organoids Technology Market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments.
The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.
Expected Revenue Growth:
The global human organoids market size is projected to reach USD 1,901 million by 2025 from USD 850 million in 2020, at a CAGR of 17.5% during the forecast period.
Download PDF [email protected]
Driver: Growing focus on developing alternatives for animal testing models
Animal models are widely used in biomedical research for human-specific diseases. However, there are various cases that demonstrate that animal models cannot always be predictive for human drug response, like in the case of drug toxicology studies. This is because there are wide variations in the metabolism of drugs and toxins in humans as compared to animals, which makes it nearly impossible to study drug metabolism in experimental models such as laboratory rodent species. Additionally, in recent years, several regulations have been implemented that restrict the use of animals in research activities globally. Similarly, several bodies, such as Cruelty Free International and the Fund for the Replacement of Animals in Medical Experiments, oppose the use of animal-based models for research purposes.
It is necessary to develop alternative testing models that can provide an environment with maximum equivalence to that of the human body. Considering this, various institutes are involved in developing alternative methods for drug development and biomedical research. As organoids can serve as alternatives to animal models, the current focus on reducing animal use in research is expected to support the growth of the human organoids market.
Opportunity: Increasing focus on drug discovery activities
The increasing demand for new and advanced drugs is driving the overall pace of drug discovery and research. This is the major factor responsible for the rising number of clinical trials conducted for studying and commercializing new drugs. According to ClinicalTrials.gov, the total number of clinical trial studies in 2020 was estimated at 356,282.
A recent study conducted by the Hubrecht Institute states that organoids have the potential to make expensive drugs more cost-effective by identifying patients who are not likely to benefit from the drug. The significant growth in the number of clinical trials across the globe is expected to drive the demand for advanced medical technologies, including organoid models.
Kidney estimated to be the growing market
The kidney human orgnaoids market is expected to witness sustained demand during the forecast period, owing to the high prevalence of infectious diseases across major markets (resulting in a growing number of transplant procedures), and an increasing number of life science researches in the field of specific requirements and treatment, especially across emerging countries.
North America is the largest regional market for Human Organoids
North America (comprising the US and Canada) dominates the human orgnaoids market. North America is a mature market, with high penetration of human organoids technologies among key end users (pharmaceuticals & biotechnology companies, CROs, academia and others) and well-established distribution channels for human organoids product manufacturers and suppliers. Easy accessibility to and the high adoption of advanced technologies due to the significant per capita annual healthcare expenditure by the US and Canadian governments, as well as supportive government regulations, are driving the growth of the human organoids market in this region.
Request Sample [email protected]
Global Key Players:
Prominent players in Human Organoids Technology Market BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441